Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Dec;19(12):2007-11.
doi: 10.1093/annonc/mdn429. Epub 2008 Jul 29.

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

I J Diel  1 , A Jaschke, E F Solomayer, C Gollan, G Bastert, C Sohn, F Schuetz
Affiliations
Randomized Controlled Trial

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up

I J Diel et al. Ann Oncol. 2008 Dec.

Abstract

Background: Adding oral clodronate to postoperative adjuvant breast cancer therapy significantly improves disease-free survival (DFS) and overall survival (OS). Long-term follow-up data from the prospective, randomized, controlled study are reported.

Patients and methods: Patients with primary breast cancer received clodronate 1600 mg/day for 2 years or no treatment along with standard adjuvant breast cancer treatment.

Results: Analysis of 290 of 302 patients demonstrated that a significant improvement in OS was maintained in the clodronate group at a median follow-up of 103 +/- 12 months; 20.4% of patients in the clodronate group versus 40.7% of control group patients (P = 0.04) died during the 8.5 years following primary surgical therapy. Significant reductions in the incidence of bony and visceral metastases and improvement in duration of DFS at 36- and 55-month follow-up periods were no longer seen with clodronate.

Conclusion: These long-term survival data extend the survival advantage reported in previous studies with oral clodronate in breast cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of bone metastasis-free survival among patients treated with oral clodronate compared with standard follow-up therapy (N = 209).
Figure 2.
Figure 2.
Kaplan–Meier curve of visceral metastasis-free survival among patients treated with oral clodronate compared with standard follow-up therapy (N = 209).
Figure 3.
Figure 3.
Kaplan–Meier curve of overall survival among patients treated with oral clodronate compared with standard follow-up therapy (N = 209).
See this image and copyright information in PMC

References

    1. American Cancer Society. Breast Cancer Facts and Figures, 2003–2004. American Cancer Society Inc.; 2003. . American Cancer Society, Atlanta, GA, USA.
    1. Ferlay J, Bray P, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. IARC Press; 2004.
    1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66. - PMC - PubMed
    1. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001;61:1253–1274. - PubMed
    1. Paterson AH. The role of adjuvant therapy with bisphosphonates in cancer. Am J Cancer. 2004;3:25–39.

Publication types

MeSH terms